NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/02/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8.6 mln
Float29.07 mln
Earnings Date10/06/2026
Relative Strength
93
/ 100
Top performer
Debt / Equity
-10.85
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
ROA
-672
Deeply negative
Business Description
Liminatus Pharma is a California-based drug development company focused on finding new ways to treat cancer. Founded in 2018, the company is working on an antibody treatment designed to help the body's own immune system recognize and attack tumor cells more effectively. Unlike some similar approaches, their lead treatment is engineered to avoid damaging red blood cells, which has been a common problem in this area of research.